Chuck Grassley (R-IA) (via AP Images)

Bi­par­ti­san trio of sen­a­tors ask FTC to look at PBMs and tac­tics to keep in­sulin prices high

Just this week, the Sen­ate vot­ed 51-50 along par­ty lines (with tie break­er from VP Ka­mala Har­ris) to make Pres­i­dent Biden ap­pointee Al­varo Bedoya the de­cid­ing vote on a split 2-2 Fed­er­al Trade Com­mis­sion. And now that it is no longer split, a group of sen­a­tors wants the com­mis­sion to ac­tu­al­ly move for­ward on in­ves­ti­gat­ing phar­ma­cy ben­e­fit man­agers.

Re­pub­li­can sen­a­tors Chuck Grass­ley (IA) and Mike Braun (IN), along­side De­mo­c­rat sen­a­tor Ron Wyden (OR), sub­mit­ted a let­ter to FTC chair Lina Khan ear­li­er this week, af­ter the com­mis­sion­ers re­mained dead­locked in a 2-2 vote in Feb­ru­ary to for­mal­ly look in­to an­ti-com­pet­i­tive prac­tices at the hands of PBMs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.